WO2017164752A1 - Liquide de refroidissement, procédé, dispositif et cathéter péricardique pour l'hypothermie cardiaque et l'application du liquide de refroidissement - Google Patents

Liquide de refroidissement, procédé, dispositif et cathéter péricardique pour l'hypothermie cardiaque et l'application du liquide de refroidissement Download PDF

Info

Publication number
WO2017164752A1
WO2017164752A1 PCT/PL2016/000159 PL2016000159W WO2017164752A1 WO 2017164752 A1 WO2017164752 A1 WO 2017164752A1 PL 2016000159 W PL2016000159 W PL 2016000159W WO 2017164752 A1 WO2017164752 A1 WO 2017164752A1
Authority
WO
WIPO (PCT)
Prior art keywords
pericardial
cooling liquid
cooling
heart
catheter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/PL2016/000159
Other languages
English (en)
Inventor
Tomasz KAMECZURA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PL416583A external-priority patent/PL416583A1/pl
Priority claimed from PL419782A external-priority patent/PL419782A1/pl
Application filed by Individual filed Critical Individual
Publication of WO2017164752A1 publication Critical patent/WO2017164752A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/12—Devices for heating or cooling internal body cavities
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/0085—Devices for generating hot or cold treatment fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0059—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit
    • A61F2007/0063—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit for cooling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F7/12—Devices for heating or cooling internal body cavities
    • A61F2007/126—Devices for heating or cooling internal body cavities for invasive application, e.g. for introducing into blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
    • A61M25/09—Guide wires
    • A61M2025/09116—Design of handles or shafts or gripping surfaces thereof for manipulating guide wires
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes

Definitions

  • the present invention is a cooling liquid, a method, a device and a pericardial catheter for heart hypothermia and an application of the cooling liquid, which are intended to reduce the temperature of the heart, and therefore change the level of metabolism of the heart muscle during myocardial infarction, arrhythmia and other need to reduce the oxygen metabolism of the heart tissue, for example in the bridging procedure in patients with advanced ischemic heart disease for heart transplant as well as cardio-protective therapy in such surgical treatments as TAVI, BAV, etc.
  • Myocardial infarction arises from sudden coronary artery occlusion.
  • the myocardial area supplied by the artery is cut off from the blood supply and hence oxygen and nutrients, which causes necrosis of part of the heart.
  • the larger vessel is occluded, the larger area of the heart undergoes necrosis.
  • the larger area of the heart undergoes necrosis, the weaker becomes the heart and respectively shorter the patient survival.
  • Previously used therapeutic hypothermia is the method for lowering the temperature of the entire body of the patient to about 32 ⁇ 34 ° C and it has been known for several years.
  • the most widely used therapeutic hypothermia is used to limit the brain damage in patients after cardiac arrest or cerebrospinal injuries.
  • a clinical study clearly showed that the application of hypothermia therapy in patients after hospital cardiac arrest significantly reduces mortality, as shown in the publication by Bernard S. A. Jones, B. ML, Home M. K., Clinical trial of induced hypothermia in comatose survivors of out-of-hospital cardiac arrest. Ann Emerg Mod August 1997; 30:146-15.
  • this procedure requires additional procedures, such as sedation of the patient, skeletal muscle relaxation, and application of mechanical ventilation.
  • the cooling liquid for the heart hypothermia intended to be placed into the heart pericardial sac, is characterized in that it comprises crystalloid or, depending on the clinical needs, crystalloid with substances neutralizing harmful by-products of ROS oxygen metabolism.
  • Crystalloid preferably is in the cooling liquid in the form of an aqueous solution of Nail having a concentration of 0.9% by weight, and neutralizing substances contain the following per 100 ml of NaCl solution: glutathione GSH in an amount of 1200 mg, selenium Se in an amount of 14 mg, retinol (vitamin A) in an amount of 2 mg, alpha-tocopherol (vitamin E) in an amount of 100 mg and ascorbic acid in an amount of 100 mg. Further advantages are obtained if the cooling liquid contains a dose of the ant arrhythmic drug, which contains a mixture of amiodarone and glucose of a concentration of 5% ⁇ 10% by weight.
  • the method of the heart hypothermia is characterized in that the heart is cooled directly by the cooling liquid introduced through pericardial catheter, using cooling tubes, to the heart pericardial sac, wherein when introducing of the cooling liquid, its quantity introduced into the pericardial sac and discharged from it, and the temperature and pressure of the pericardial sac liquid mixture with cooling liquid inside the pericardial sac are monitored.
  • the temperature inside the pericardial sac is, depending on the clinical needs, maintained in the range from 10 ° C to 36 ° C.
  • the first stage before the introduction of the cooling liquid into the pericardial sac, it is punctured with a needle having a central bore, whereupon, a guidewire is introduced into the pericardial sac through the axial bore of the needle, after removal of the needle from the guidewire pericardial catheter sealed with a guide with handle is slidden over it, and pericardial catheter is introduced into the pericardial sac, and then, after the proper placement of the pericardial catheter in the pericardial sac, the guide is detached, it is ejected from the pericardial sac, and then the guidewire is removed.
  • cooling tubes and test probe are introduced into the pericardial sac through the pericardial catheter.
  • cooling tubes and the test probe are sealed in the pericardial catheter, while forming a tight system closed for circulation of the cooling liquid in the pericardial sac and its outside.
  • the device for the heart hypothermia is characterized in that it comprises a pericardial catheter through winch the cooling tubes with the cooling liquid and the test probe are with their ends introduced into the pericardial sac of the cooled heart, and their second ends are connected to the power supply and control unit, provided with at least one pump of the cooling liquid and cooling unit of the cooling liquid, and the controller of that pump and cooling unit, wherein the second ends of the cooling tubes are through the flow sensors connected with the pump and the cooling unit, and the second end of the test probe is connected to the input of the controller, and preferably outputs of that flow sensor are connected to further inputs of that controller.
  • the pericardial catheter of the device is shaped like an elongated cylinder in front ended with a conical tip, and has main duct ended at the tip and located in its axis for the test probe and two lateral ducts parallel to the main duct, ended in front of the pericardial catheter, on its cylindrical surface, with lateral openings for cooling tubes, and in the rear part of the pericardial catheter the cooling tubes, and the test probe are sealed in it with a flexible valve covered by a cylindrical lid, which is snap mounted on the circumferential protrusion of the pericardial catheter, and moreover, after the introduction of the pericardial sac into the pericardial catheter it is sealed with a guide with a handle.
  • the cooling tube is ended at its end embedded in the pericardial sac with longitudinal apertures spaced around its circumference
  • the test probe is at its end embedded in the pericardial sac ended with temperature and pressure sensors, and on the opposite side with a plug, whereby connection of the test probe with the input of the controller is through the test tube, and moreover the cooling unit of the power supply and control unit has a cooling coil placed in a tray for the cooling liquid.
  • the apparatus further comprises a guide with a handle which is provided with a central passage duct for the guidewire, and the handle of the guide has two plugging lateral ducts of the pericardial catheter when introduced into the pericardial sac.
  • the pericardial catheter for hypothermia of the heart, is characterized in that, is shaped like an elongated cylinder in front ended with a conical tip, and has main duct ended at the tip and located in its axis and two lateral ducts parallel to the main duct, ended in front of the pericardial catheter, on its cylindrical surface, with lateral openings , and in the rear part of the pericardial catheter a flexible valve, with a covered cylindrical lid is embedded, which is snap mounted on the circumferential protrusion of the pericardial catheter, and moreover, after the introduction of the pericardial sac into the pericardial catheter it is sealed with a guide with a handle, which is provided with a central passage duct and has two plugging tubes lathered ducts of the pericardial catheter in its introduction into the pericardial sac.
  • cooling liquid for heart hypothermia intended for mechanical introduction and removal from pericardial sac with the use of pericardial catheter for the purpose of direct heart cooling, based on the invention is characterized by the fact that it is a water solution of a substance with temperature lower than the organism to which it is introduced.
  • the cooling liquid contains as a substance at least one substance neutralizing Reactive Oxygen Species (ROS), and the advantageous content of neutralizing substances in 100 ml of solution occurs in the following: 1200 mg of glutathione (GSH), 14 ⁇ g of selenium, 2 mg of retinol (vitamin A), 100 mg of alfa-tocopherol (vitamin E) and 100 mg of ascorbic acid.
  • ROS Reactive Oxygen Species
  • the cooling liquid contains a dose of anti-arrhythmic drug, while as the dose of anti-arrhythmic drug it contains mixture of amiodarone and glucose of a concentration of 5% ⁇ 10% by weight.
  • cooling liquid based on the invention is characterized by the fact that it is used for direct heart hypothermia by means of introduction of chilled cooling liquid to pericardial sac, monitoring the amount of cooling liquid introduced to pericardial sac and released therefrom as well as monitoring the temperature and pressure of the mixture of pericardial sac liquid and cooling liquid inside pericardial sac.
  • the cooling liquid maintains the temperature inside pericardial sac during heart hyporaermia within the following limits: from 10 °C to 36 °C.
  • the described cooling liquids and method of direct heart hypothermia for the treatment of myocardial infarction have not previously been used in cardiology, and moreover it allows to affect the metabolic rate of muscle tissue of the heart, and by reducing the extent of necrosis it limits the damage to the heart after myocardial infarction, and thus affects the survival and the quality of life of patients.
  • the method of the direct heart hypothermia using the device allows to keep the state of consciousness of the patient, eliminates the need for intubation and artificial ventilation.
  • the introduction of the cooled cooling liquid directly into the pericardial sac a direct effect on the heart muscle is possible.
  • the level of metabolism of the heart muscle will be reduced, and thus the area of damage in myocardial infarction will be limited.
  • Recommendations for direct heart hypothermia include myocardial infarction, malignant an-hythmias and other needs for decreasing aerobic metabolism of heart tissue, such as e.g. bridge therapy for heart transplant in patients with advanced ischemic heart disease for heart transplant and also as cardioprotective therapy in surgical treatments such as: TAVI, BAV, etc.
  • a system to be used in medicine was developed for quick and immediate reduction in the temperature of the heart muscle during myocardial infarction, and thus maximally quick release of the metabolism of the heart, which directly translates to the extent of myocardial infarction, and thus the survival of patients.
  • Innovation of solutions according to the invention is to optimize of further, except the time of intervention and introducing PCI (Percutaneous coronary Interventions) as a method of treating, mortality reducing factor - metabolism of the heart tissue.
  • PCI Percutaneous coronary Interventions
  • the reduced cooling liquid temperature in the pericardial sac significantly slows the metabolic processes of the muscle, reducing the production of free radicals, slowing the production of other harmful products of metabolism and change of pH.
  • reduction of tire heart tissue temperature stabilizes the cell membrane potential, thereby reducing the tendency to malignant arrhythmia in myocardial infarction.
  • the invention is also applicable in the course of electrical storms, recurring arrhythmias, which are difficult to deal with by means of classical pharmacotherapy, as a bridge therapy for heart transplant in advanced ischemic heart disease.
  • the device was designed so that in addition to the possibility of "cooling the metabolism" of myocardium and antioxidant therapy, wherein the cooling liquid in addition to the cooling function can perform a reducing function, i.e., has the capacity to neutralize harmful products of ROS oxidative metabolism (Reactive Oxygen Species), for example, such as superoxide anion 0 2 ⁇ -, hydroperoxide radical ⁇ 2 ⁇ , it being possible to apply virtually any drug in the form of solution for injection by administering a suitable dose to the closed cooling liquid circuit of the device.
  • ROS oxidative metabolism reactive Oxygen Species
  • This possibility is particularly important in patients with severe arrhythmias in the course of extensive myocardial infarction (such as amiodarone), or in the case of cardiogenic shock, when any number of catecholamines may be added to the system of direct hypothermia of the heart.
  • the advantage of the invention is no need for sedation of the patients and sagging of skeletal muscles, as in the case of other therapeutic hypothermia. This feature allows maintaining a constant state of consciousness in the course of therapy in the intensive care ward and excludes any complications resulting from the use of sedatives, depolarizing neuromuscular junction and respiratorotherapy.
  • Fig. 1 shows the device according to the invention, as a scheme
  • Fig. 2 pericardial catheter plugged with the guide with a handle in a perspective view from the front, sid eand top
  • Fig. 3 - the same pericardial catheter with the guide with a handle in a perspective dispersed view from the front, sid eand top
  • Fig. 4 ⁇ 6 show pericardial catheter, respectively in a longitudinal section of the main duct, a longitudinal section of the lateral ducts and perspective front, side and top views
  • Fig. 1 shows the device according to the invention, as a scheme
  • Fig. 2 - pericardial catheter plugged with the guide with a handle in a perspective view from the front, sid eand top
  • Fig. 3 - the same pericardial catheter with the guide with a handle in a perspective dispersed view from the front, sid eand top
  • Fig. 4 ⁇ 6 show pericardial catheter, respectively in a longitudinal
  • Fig. 10 shows a pericardial catheter with the introduced cooling tubes and the test probe in front, side and top perspective view
  • Fig. 1 1 ⁇ 13 showing the lid of the pericardial catheter, respectively in a perspective front and lateral view, front view and longitudinal section
  • Fig. 16 ⁇
  • FIG. 19 shows the test probe with the connector in a side view, Fig. 20 - pericardial catheter with cooling tubes and probe inserted to the heart, as a scheme, Fig. 21 - chest with the location of the heart and its adjacent elements in longitudinal section, and Figures 22 ⁇ 24 show sequential stages of the pericardial catheter introduction into the pericardial sac, in the longitudinal sections on Figures 22 and 23 and cross-section of the pericardial sac on Fig. 24.
  • the cooling liquid 1 for the heart 2 hypothermia in an embodiments is intended for its introduction into the heart 2 pericardial sac 3.
  • the cooling liquid comprises crystalloid in the form of an aqueous solution of NaCl having a concentration of 0.9% by weight.
  • the cooling liquid 1 further comprises substances neutralizing harmful by-products of ROS oxygen metabolism, which comprise the following per 100 ml of the NaCl solution: glutathione GSH in an amount of 1200 mg, selenium Se in an amount of 14 mg, retinol (vitamin A) in an amount of 2 mg, alpha-tocoplierol (vitamin E) in an amount of 100 mg and ascorbic acid in an amount of 100 mg.
  • the coo ling liquid 1 in addition to the aforementioned components, comprises a dose of the ant arrhythmic drug in the form of a mixture of amiodarone and glucose and a concentration of 5% ⁇ 10% by weight.
  • the developed cooling liquid 1 is characterized by a high reducing potential. Its chemical composition outside the function of direct cooling of the heart muscle (myocardium) has the ability to neutralize harmful products of ROS oxygen metabolism. Reducing substances such as glutathione, selenium, retinol, alpha-tocopherol and ascorbic acid, used in optimum concentrations in an extremely efficient way absorb and inactivate reactive oxygen species (ROS) arising during acute myocardial ischemia.
  • ROS reactive oxygen species
  • the heart 2 is cooled directly by the cooling liquid 1 introduced through pericardial catheter 4, using cooling tubes 5, to the heart 2 pericardial sac 3,
  • the cooling liquid 1 introduced through pericardial catheter 4, using cooling tubes 5, to the heart 2 pericardial sac 3
  • the temperature and pressure of the pericardial sac 3 liquid mixture with cooling liquid 1 inside the pericardial sac 3 are monitored.
  • the temperature inside the pericardial sac 3 is maintained in the range from 10 ° C to 36 ° C, depending on the patient's clinical condition.
  • a guidewire 7 is introduced into the pericardial sac 3 through the axial bore of the needle 6, after removal of the needle 6 from the guidewire 7 pericardial catheter 4 sealed with a guide 8 with handle is slidden over it, and pericardial catheter 4 is introduced into the pericardial sac 3, and then, after the proper placement of the pericardial catheter 4 in the pericardial sac 3, the guide 8 is detached, it is ejected from the pericardial sac 3, and then the guidewire 7 is removed.
  • cooling tubes 5 and test probe 10 are introduced into the pericardial sac 3 through the pericardial catheter 4. Cooling tubes 5 and the test probe 10 are sealed in the pericardial catheter 4, while forming a tight system closed for circulation of the cooling liquid 1 in the pericardial sac 3 and its outside.
  • the method of the invention involves direct cooling of myocardium in pericardial sac 3, which allows for cooling of the outer layer 2 of myocardium.
  • pericardial sac 3 which allows for cooling of the outer layer 2 of myocardium.
  • studies are planned to determine the optimal target temperature of the heart 2.
  • the procedure of introducing the pericardial catheter 4 into the pericardial sac 3 consists of several stages. In the first stage, access to the pericardial sac 3 must be obtained by the same puncturing as for the pericardiocentesis. After puncturing the pericardial sac 3 with the needle 6 and the confirmation of the successful puncture by drawing a small amount of the liquid from the pericardial sac 3 to the first syringe (not shown on the figure) the guidewire 7 is introduced to the pericardial sac 3 through the needle 6.
  • the needle 6 is removed from the pericardial sac 3 from the guidewire 7 and is completely slipped out of the guidewire 7 in the direction of the patient, and the pericardial catheter 4 sealed by the guide 8 with a handle 9 overlaps the distal part of the guidewire 7, coming out of the pericardial sac 3 through the body shell, and the pericardial catheter 4 is introduced into the pericardial sac 3.
  • the guide 8 is with the other hand moved with pericardial catheter 4 towards the pericardial body shells so as to introduce the pericardial catheter 4 into the pericardial sac 3 of the patient.
  • pericardial catheter 4 Before the introduction of the pericardial catheter 4 to pericardial sac 3 a small incision of the skin is performed, so that the pericardial catheter 4 with a guidewire 8 could be introduced into the pericardial sac 3 with the least resistance. After the proper placement of the pericardial catheter 4 in the pericardial sac 3 guide 8 is detached from the pericardial catheter 4, and then in one smooth movement it is removed after the guidewire 7, then the guidewire 7 itself is removed.
  • the pericardial catheter 4 is introduced into the pericardial sac 3 using known methods of the imaging testing (fluoroscopy, echocardiography), during the second stage cooling tubes 5 and test probe 10 are introduced to the pericardial sac 3 through the pericardial catheter 4.
  • the cooling consists in injecting the cooling liquid 1 into the pericardial sac 3 via a cooling tube 5 (cooled to a predetermined temperature) and receipt of the same volume of the cooling liquid 1 per unit of time via the second cooling tube 5 in a closed circuit.
  • Pericardial catheter 4 is designed as to match the pericardial sac 3 to create a tight closed circuit for the continuous circulation of the mixture of the pericardial sac 3 liquid and the cooling liquid 1, wherein it is also possible to introduce additional pharmacological substance into the circuit.
  • the device 11 for the heart 2 hypothermia in an embodiment, comprises a pericardial catheter 4 through which the cooling tubes 5 with the cooling liquid 1 and the test probe 10 are with their ends introduced into the pericardial sac 3 of the cooled heart 2, and their second ends are connected to the power supply and control unit 12, provided with one pump 13 of the cooling liquid 1 and cooling unit 14 of the cooling liquid 1, and the controller 15 of that pump 13 and cooling unit 14,
  • the second ends of the cooling tubes 5 are through the flow sensors 16 connected with the pump 13 and the cooling unit 14, the second test probe 10 is connected to the input of the controller 15, and outputs of those flow sensors 16 are connected to further inputs of that controller 15.
  • the pericardial catheter 4 is shaped like an elongated cylinder in front ended with a conical tip, and has main duct 17 ended at the tip and located in its axis for the test probe 10 and two lateral ducts 18 parallel to the main duct 17, ended in front of the pericardial catheter 4, on its cylindrical surface, with lateral openings 19 for cooling tubes 5, And in the rear part of the pericardial catheter 4 the cooling tubes 5, and the test probe 10 are sealed in it with a flexible valve 20 covered by a cylindrical lid 21, which is snap mounted on the circumferential protrusion of the pericardial catheter,
  • the cooling tube 5 is ended at its end embedded in the pericardial sac 3 with longitudinal apertures 23 spaced around its circumference,
  • the test probe 10 is at its end embedded in the pericardial sac 3 ended with temperature and pressure sensors, and on the opposite side with a plug 24, whereby connection of the test probe 10 with the input of the controller 25 is through the test tube 25.
  • the temperature sensor of the test probe 10 regulates the operation of the power supply and control unit 12 of the devices 11, and the pressure sensor of the test probe 10 is responsible for a continuous monitoring of the pressure of the cooling liquid 1 in the pericardial sac 3.
  • the temperature of the cooling liquid 1 as the pressure in the pericardial 3 sets manually using the controller 15 as an integral part of the device 11.
  • the cooling unit 14 of the power supply and control unit 12 in the device 11 has a cooling coil 26 placed in a tray 27 for the cooling liquid 1.
  • the device 11 comprises a guide 8 with a handle 9, which is provided with a central passage duct 33 for a guidewire 7.
  • Handle 9 of the guide 8 has two tubes plugging 34 the lateral ducts 18 of the pericardial catheter 4 when it is introduced into the pericardial sac 3.
  • the pericardial catheter 4 in an embodiment, for hypothermia of the heart 2 is shaped like an elongated cylinder in front ended with a conical tip, and has main duct 17 ended at the tip and located in its axis and two lateral ducts 18 parallel to the main duct 17, ended in front of the pericardial catheter 4, on its cylindrical surface, with lateral openings 19, and in the rear part of the pericardial catheter 4 a flexible valve 20, with a covered cylindrical lid 21 is embedded, which is snap mounted on the circumferential protrusion of the pericardial catheter 4, and moreover, after the introduction of the pericardial sac 3 into the pericardial catheter 4 it is sealed with a guide 8 with a handle. 9, which is provided with a central passage duct 33 and has two plugging tubes 34 lathered ducts 18 of the pericardial catheter 4 in its introduction into the pericardial sac 3.
  • cooling tubes 5 and the test probe 10 introduced into the pericardial sac 3 through the pericardial catheter 4 do not adhere too strongly to the cardiac wall and/or the inner surface of the pericardial sac 3, since with this arrangement a free circulation of the cooling liquid 1 in the pericardial sac 3 is possible and the risk of perforation is minimized.
  • cooling tubes 5 are connected to the tray 27 with the cooling liquid 1 and the test probe 10 with the test tube 25 of the controller 15, and then using the two second syringes 30 and containers 32 for the air and the cooling liquid 1 the air from the cooling tubes 5 is removed. After entering the manual setting on the controller 15 and connecting the tray 27 with cooling liquid 1 the process of direct heart 2 hypothermia begins.
  • the device 11 has built-in sensors that continuously record the amount of the cooling liquid 1 entering into the pericardial sac 3, the amount of the cooling liquid 1 living the pericardial sac 3, the temperature of the cooling liquid 1 and the pressure of the pericardial sac 3. Thanks to the applied sensors an excellent control of the temperature of the myocardium of the ventricles, possibility of its smooth adjustment and adaptation to the current clinical condition of the patient are achieved, as well as the possibility of a dangerous increase or decrease in the pressure of liquid in the pericardial sac 3 is eliminated.
  • Flow sensors 16 sensors of temperature and pressure installed on the device 11 after recording a significant deviation from the programmed settings cause the immediate stop of the device 11 and the activation of the audio signal.
  • Fig. 21 the location of the heart 2 and its adjacent elements is shown in the form of pericardial cavity 35, spine 36, chest 37 wall and diaphragm 38, and Fig. 22 ⁇ 24 show further stages of introducing the pericardial catheter 4 into the pericardial sac 3.
  • cooling liquid 1 for heart hypothermia 2 based on the invention in a fourth and a fifth example of execution is intended to be mechanically introduced and discharged from pericardial sac 3 with the use of pericardial catheter 4 to cause direct heart cooling 2, whereas cooling liquid 1 is a water solution of the substance and its temperature is lower than the organism to which it is introduced.
  • cooling liquid 1 contains substances neutralizing harmful products of aerobic metabolism (OS), which contain the following in 100 ml of solution: 1200 mg of glutathione (GSH), 14 ⁇ g of selenium, 2 mg of retinol (vitamin A), 100 mg of alfa-tocopherol (vitamin E) and 100 mg of ascorbic acid, whereas cooling liquid 1 contains optional crystalloid.
  • OS harmful products of aerobic metabolism
  • cooling liquid contains identical components as in the first example, moreover, it contains a dose of anti- airhythmia drug in the form of mixture of amiodarone and glucose with mass concentration of 5% ⁇ 10%.
  • cooling liquid 1 based on the invention in the fourth example of execution is aimed at direct heart hypothermia 2 by means of introducing chilled cooling liquid 1 to pericardial sac 3 of the heart 2, monitoring the amount of cooling liquid 1 introduced to and discharged from pericardial sac 3, and monitoring temperature and pressure of the mixture of pericardial sac liquid 3 with cooling liquid 1, inside pericardial sac 3.
  • the cooling liquid 1 in the fourth and fifth example of execution has similar properties to the cooling liquid 1, winch is described in the examples from the first to the third, and it holds the same use.
  • the invention is applicable in lowermg temperature of heart 2 in the course of myocardial infarction 2, arrhythmia and in other need to decrease aerobic metabolism of heart tissue 2, for example in bridge therapy in advanced ischemic heart 2 disease for heart 2 transplant and as cardio -protective procedure during surgical treatment such as TAVI, BAV, etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)

Abstract

L'invention concerne un fluide de refroidissement (1) qui est conçu pour être introduit dans le péricarde (3) du cœur (2) et qui contient un cristalloïde ou un cristalloïde comportant des substances neutralisant les produits nocifs du métabolisme de l'oxygène. Selon une autre version, le fluide de refroidissement (1) contient une dose de médicament anti-arythmisant. Le cœur (2) est refroidi directement par le fluide de refroidissement (1) introduit par un cathéter péricardique (4) par des conduites de refroidissement (5) dans le péricarde (3). La quantité de fluide de refroidissement (1) introduit et retiré dans le péricarde (3) ainsi que sa température et sa pression à l'intérieur du péricarde (3) est contrôlée. La température dans le péricarde (3) est régulée en fonction des exigences cliniques dans la plage comprise entre 10 °C et 36 °C. Le sujet de l'invention est également un autre dispositif (11), un cathéter péricardique (4) et un autre fluide de refroidissement et son utilisation qui permet le maintien de la température dans la plage comprise entre 10 °C et 36 °C à l'intérieur du péricarde (3) pendant l'hypothermie cardiaque (2). L'invention sert à l'hypothermie cardiaque (2) directe en cas d'arrêt cardiaque (2), d'arythmie et dès lors qu'il est nécessaire de réduire le métabolisme de l'oxygène de tissu cardiaque (2), par exemple dans le cas de pontage, dans une maladie avancée de l'artère coronaire (2), dans la transplantation cardiaque (2), et peut être utilisée en tant que cardioprotection dans des procédures de type ITVA et valvuloplastie aortique, etc.
PCT/PL2016/000159 2016-03-22 2016-12-30 Liquide de refroidissement, procédé, dispositif et cathéter péricardique pour l'hypothermie cardiaque et l'application du liquide de refroidissement Ceased WO2017164752A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PL416583A PL416583A1 (pl) 2016-03-22 2016-03-22 Płyn chłodzący,sposób, urządzenie i cewnik osierdziowy do hipotermii serca
PLP.416583 2016-03-22
PL419782A PL419782A1 (pl) 2016-12-13 2016-12-13 Płyn chłodzący do hipotermii serca i jego zastosowanie
PLP.419782 2016-12-13

Publications (1)

Publication Number Publication Date
WO2017164752A1 true WO2017164752A1 (fr) 2017-09-28

Family

ID=59899135

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2016/000159 Ceased WO2017164752A1 (fr) 2016-03-22 2016-12-30 Liquide de refroidissement, procédé, dispositif et cathéter péricardique pour l'hypothermie cardiaque et l'application du liquide de refroidissement

Country Status (1)

Country Link
WO (1) WO2017164752A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021031616A1 (fr) * 2019-08-20 2021-02-25 中国人民解放军总医院 Dispositif à micro-cathéter triple et procédé d'injection intramyocardique transthoracique et épicardique sous guidage par ultrasons
WO2021138252A1 (fr) * 2019-12-31 2021-07-08 Miraki Innovative Think Tank Llc Solution froide pour induire une hypothermie thérapeutique

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6206004B1 (en) * 1996-12-06 2001-03-27 Comedicus Incorporated Treatment method via the pericardial space
RU2270008C1 (ru) * 2005-05-19 2006-02-20 Юрий Георгиевич Доронин Средство и способ повышения устойчивости человека и животных к гипотермии активированием жизненно важных биохимических процессов
WO2009012534A1 (fr) * 2007-07-25 2009-01-29 Hibernation Therapeutics Limited Protection, préservation et récupération d'organe amélioré

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6206004B1 (en) * 1996-12-06 2001-03-27 Comedicus Incorporated Treatment method via the pericardial space
RU2270008C1 (ru) * 2005-05-19 2006-02-20 Юрий Георгиевич Доронин Средство и способ повышения устойчивости человека и животных к гипотермии активированием жизненно важных биохимических процессов
WO2009012534A1 (fr) * 2007-07-25 2009-01-29 Hibernation Therapeutics Limited Protection, préservation et récupération d'organe amélioré

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"punkt 4.2 Dawkowanie i sposób podawania", CORDARONE : CHARAKTERYSTYKA PRODUKTU LECZNICZEGO, 2 June 2008 (2008-06-02), pages 10 - 13, Retrieved from the Internet <URL:http://www.sanofi-aventis.com.pl/produkty/Nasze%20produkty/Cordarone_50mg_ml_roztwor_do_wstrzykiwan_-_charakterystyka_produktu.pdf> *
D.R. WHEELDON ET AL.: "A simple cooling circuit for topical cardiac hypothermia", THORAX, vol. 31, 1976, pages 565 - 571, XP055423837 *
DAVE RAVI H. ET AL.: "Hypothermic, Closed Circuit Pericardioperfusion: A Potential Cardioprotective Technique in Acute Regional Ischemia", JACC, vol. 31, no. 7, 7 June 1998 (1998-06-07), pages 1667 - 1671, XP055423838 *
PAULINA KOTAT, PTYNOTERAPIA - KRYSTALOIDY, 8 March 2009 (2009-03-08), Retrieved from the Internet <URL:http://www.machala.info/media/repository/lntensywna/34_Plynoterapia_w_oparciu%20o%20krystaloidy_Opr._Kolat_P.pdf> *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021031616A1 (fr) * 2019-08-20 2021-02-25 中国人民解放军总医院 Dispositif à micro-cathéter triple et procédé d'injection intramyocardique transthoracique et épicardique sous guidage par ultrasons
WO2021138252A1 (fr) * 2019-12-31 2021-07-08 Miraki Innovative Think Tank Llc Solution froide pour induire une hypothermie thérapeutique

Similar Documents

Publication Publication Date Title
US11351345B2 (en) Systems and methods for selective auto-retroperfusion along with regional mild hypothermia
CN110446523B (zh) 用于重症护理的血管内灌流增强
AU2006304877B2 (en) Method and apparatus for peritoneal hypothermia and/or resuscitation
US6206004B1 (en) Treatment method via the pericardial space
US20070213671A1 (en) Infusion catheter system with telescoping cannula
US20030097082A1 (en) Methods and apparatuses for navigating the subarachnoid space
EP2353501A1 (fr) Dispositif de post-conditionnement contrôlé d&#39;informatique
JP7313698B2 (ja) 穿刺システム
CN115052651B (zh) 输注导管和使用方法
US20230191089A1 (en) Cardiopulmonary Resuscitation Catheter and Related Systems and Methods
AU2018237167A1 (en) Combined stent reperfusion system
Longatti et al. Endoscopic management of intracerebral hemorrhage
CN111093543A (zh) 在较低消融压力下具有较大尺寸可调节性的冷冻球囊
WO2021138252A1 (fr) Solution froide pour induire une hypothermie thérapeutique
WO2017164752A1 (fr) Liquide de refroidissement, procédé, dispositif et cathéter péricardique pour l&#39;hypothermie cardiaque et l&#39;application du liquide de refroidissement
US20190059908A1 (en) Apparatus, system and method for treating hemorrrhage
US11166729B2 (en) Method and device for secluding a body vessel
US20180104456A1 (en) Venous anatomy drug delivery balloon
JP7689763B2 (ja) 経心筋ジェット灌流デバイス
PL241336B1 (pl) Urządzenie do hipotermii serca
WO2023148069A1 (fr) Agencement de cathéter double et système de reperfusion d&#39;une région de tissu ischémique par l&#39;intermédiaire d&#39;un vaisseau coronaire
BR112020015371B1 (pt) Sistema de punção
CN118987459A (zh) 球囊导管以及导管系统
WO2019207593A1 (fr) Système permettant la compression et l&#39;alignement de tissu en utilisant des ballonnets
IT201800003071A1 (it) Nuovo sistema di perfusione distale in cardiochirurgia

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16895622

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 16895622

Country of ref document: EP

Kind code of ref document: A1